2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by FANTI, P. Articles by FRANKE, A. A. Search for Related Content PubMed PubMed Citation Articles by FANTI, P. Articles by FRANKE, A. A.

Serum Levels and Metabolic Clearance of the Isoflavones Genistein and Daidzein in Hemodialysis Patients

Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky; and Cancer Research Center of Hawaii, Honolulu, Hawaii.

Correspondence to Dr. Paolo Fanti, MN564, University of Kentucky Medical Center, 800 Rose Street, Lexington, KY 40536-0084. Phone: 606-323-5048; Fax: 606-323-0232; E-mail: pfanti0{at}pop.uky.edu

Abstract. Genistein and daidzein are biologically active isoflavones that are especially abundant in soybeans. After intestinal absorption, circulating genistein and daidzein are eliminated primarily by the kidneys. This study was undertaken to assess the metabolism of genistein and daidzein in patients with end-stage renal disease (ESRD) on hemodialysis therapy, and to test whether this treatment modality can replace the lack of kidney function, with respect to the elimination of the isoflavones. Twenty-three hemodialysis patients and 10 healthy subjects were studied. While consuming a self-selected low isoflavone diet, baseline blood levels were undetectable in eight of 10 healthy subjects and in 14 of 23 dialysis patients. The remaining participants had detectable levels, with the nine dialysis patients displaying much higher blood concentrations than the two healthy control subjects. After the evening intake of one dose of an isoflavone-rich soy protein isolate drink, the early morning blood levels of genistein and daidzein were higher in seven dialysis patients than in eight healthy subjects (genistein 1271 ± 321 versus 425 ± 104, P < 0.05; daidzein 1304 ± 352 versus 292 ± 78, P < 0.05). The blood clearance of the isoflavones was studied in two healthy subjects and in three dialysis patients. Genistein and daidzein were eliminated within 2 d in the healthy subjects, but had not returned to baseline in two of three ESRD patients, 7 d after intake. The half-life of both compounds was estimated to be 10-fold longer in the ESRD patients than in the healthy subjects. Finally, genistein and daidzein levels were measured before and after dialysis in five patients, both while on their regular diet and after one dose of a soy protein isolate drink. In both instances, the dialysis treatment did not affect the blood isoflavone levels. In conclusion, approximately one-third of hemodialysis patients eating the standard American renal diet experience high blood levels of the isoflavones genistein and daidzein, while the remaining two-thirds have undetectable levels. After ingestion of isoflavone-rich food such as soy products, all patients have detectable levels that remain very high for several days due to lack of renal excretion.

This article has been cited by other articles:

				P. Fanti, R. Asmis, T. J. Stephenson, B. P. Sawaya, and A. A. Franke Positive effect of dietary soy in ESRD patients with systemic inflammation--correlation between blood levels of the soy isoflavones and the acute-phase reactants Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2239 - 2246. [Abstract] [Full Text] [PDF]

				A. Cassidy, J. E. Brown, A. Hawdon, M. S. Faughnan, L. J. King, J. Millward, L. Zimmer-Nechemias, B. Wolfe, and K. D.R. Setchell Factors Affecting the Bioavailability of Soy Isoflavones in Humans after Ingestion of Physiologically Relevant Levels from Different Soy Foods J. Nutr., January 1, 2006; 136(1): 45 - 51. [Abstract] [Full Text] [PDF]

				P. Fanti, T. J. Stephenson, I. M. Kaariainen, B. Rezkalla, Y. Tsukamoto, T. Morishita, M. Nomura, C. Kitiyakara, L. J. Custer, and A. A. Franke Serum isoflavones and soya food intake in Japanese, Thai and American end-stage renal disease patients on chronic haemodialysis Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1862 - 1868. [Abstract] [Full Text] [PDF]

				K. D. R. Setchell, N. M. Brown, P. B. Desai, L. Zimmer-Nechimias, B. Wolfe, A. S. Jakate, V. Creutzinger, and J. E. Heubi Bioavailability, Disposition, and Dose-Response Effects of Soy Isoflavones When Consumed by Healthy Women at Physiologically Typical Dietary Intakes J. Nutr., April 1, 2003; 133(4): 1027 - 1035. [Abstract] [Full Text] [PDF]

				K. D. Setchell, M. S Faughnan, T. Avades, L. Zimmer-Nechemias, N. M Brown, B. E Wolfe, W. T Brashear, P. Desai, M. F Oldfield, N. P Botting, et al. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women Am. J. Clinical Nutrition, February 1, 2003; 77(2): 411 - 419. [Abstract] [Full Text] [PDF]

				M. J. Messina and C. L. Loprinzi Soy for Breast Cancer Survivors: A Critical Review of the Literature J. Nutr., November 1, 2001; 131(11): 3095S - 3108. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673